outbrain
Close  
ASIDE FROM QUARANTINE AND CONFINEMENT COVERAGE

PhilHealth to shoulder COVID-19 testing costs – Nograles

/ 02:07 PM March 11, 2020

  

MANILA, Philippines — The Philippine Health Insurance Corporation (PhilHealth) would shoulder the costs for the 2019 coronavirus disease (COVID-19) tests, a senior Palace official announced Wednesday. 

ADVERTISEMENT

According to Cabinet Secretary Karlo Nograles, COVID-19 tests in hospitals would be covered by the state health insurance firm on top of the coverage cost for quarantine and confinement.

He said PhilHealth President and CEO Ricardo Morales informed him that the agency is now in the process of formalizing and operationalizing the new benefit.

FEATURED STORIES

“Given this, the last thing we want is for our citizens to worry about medical costs and expenses. Their only concern should be their well-being and the well-being of their families,” Nograles, a member of the Inter-Agency Task Force for the Management of Emerging Infectious Diseases, said in a statement.

To date, the Department of Health (DOH) has reported 33 confirmed cases of COVID-19 in the country, including one local transmission, which prompted the raising of Code Red Sub-Level 1 alert.

The increasing count of people infected with COVID-19 in the country likewise led to President Rodrigo Duterte’s declaration of a state of public health emergency.

COVID-19 is a respiratory disease caused by the novel coronavirus, which the International Committee on Taxonomy of Viruses named SARS-CoV-2. 

The epicenter of the SARS-CoV-2 outbreak was in China’s Wuhan City, Hubei province, and since late 2019 the virus has infected over 110,000 and killed more than 3,000 in mainland China. 

The virus causes mild symptoms such as fever and cough for most people but can cause serious illness such as pneumonia for others, especially older adults and people with existing health problems.

UP-made test kit set for field validation

Nograles, at the same time, said the government is “fast-tracking” the deployment of additional test kits to quickly identify and isolate those infected by the disease.

ADVERTISEMENT

The Food and Drug Administration earlier allowed the use of test kits developed by local scientists at the University of the Philippines-National Institute of Health (UP-­NIH).

According to Nograles, the rapid diagnostic test kit is now set for a field validation study.

“At this point, they just need to conduct validation of 500 tests for COVID-19 to enable them to conduct clinical sensitivity analysis as a pre-condition set by the FDA. Once it passes the clinical tests, the FDA will grant full access by all hospitals, as guided by the DOH,” he said.

Some private hospitals have also signified their intention to join the field validation, Nograles revealed, adding that NIH is hoping to secure by Friday the approval of the ethics committee for field validation testing.

KGA

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
EDITORS' PICK
MOST READ
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: 2019-nCoV, China, Coronavirus, COVID-19, disease, DoH, FDA, Health, Karlo Nograles, Local news, Malacañang, Nation, national news, NcoV, nCoV update, news, novel coronavirus, Outbreak, Philhealth, Philippine news updates, SARS-CoV-2, test kits, UP-NIH, Virus, Wuhan
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.